|
|
||||||||



*
Department of Medicine, Division of Rheumatology and Immunology, University of Southern California, Los Angeles, CA 90033;
Department of Immunobiology, Immunex Corporation, Seattle, WA 98101; and
Department of Immunology and Inflammation, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543
Staphylococcal superantigens, including staphylococcal enterotoxin B (SEB), promote vigorous T cell-dependent Ig responses at low dose (0.01 ng/ml). In contrast, more mitogenic high dose SEB (100 ng/ml) profoundly inhibits the Ig responses. To assess the contribution of CD8+ T cells to this inhibition, high dose SEB-dependent killing of activated B cells and down-regulation of Ig responses were determined. Rapid killing (4 h) of activated B cells was effected by high dose SEB-activated CD8+ T cells (CD8*), but not by high-dose SEB-activated CD4+ T cells (CD4*), and required the presence of high dose SEB during the cytotoxicity assay. This killing was abrogated by chelation of extracellular calcium or by treatment with concanamycin A but was only modestly affected by treatment with brefeldin A, suggesting a perforin-based pathway of killing. Despite their widely disparate abilities to rapidly kill activated B cells, CD8* and CD4* demonstrated similar quantitative abilities to effect high dose SEB-dependent down-regulation of Ig responses. Antagonist anti-CD95 mAb substantially reversed high dose SEB-dependent down-regulation effected by CD8* but had no appreciable effects on high dose SEB-dependent killing of activated B cells. These observations strongly suggest that the small fraction of activated B cells that secrete Ig are selectively sensitive to CD95-based killing but resistant to CD95-independent killing. This finding may help explain why clinical autoimmunity associated with increased titers of autoantibodies is a predominant feature of defects in CD95 or CD95 ligand.
This article has been cited by other articles:
![]() |
Y. Yan, T. Devos, L. Yu, G. Xia, O. Rutgeerts, J. Goebels, C. Segers, Y. Lin, M. Vandeputte, and M. Waer Pathogenesis of Autoimmunity After Xenogeneic Thymus Transplantation J. Immunol., June 15, 2003; 170(12): 5936 - 5946. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-U. Lee, W. Ferens, W. C. Davis, M. J. Hamilton, Y.-H. Park, L. K. Fox, J. Naessens, and G. A. Bohach Identity of Activation Molecule 3 on Superantigen-Stimulated Bovine Cells Is CD26 Infect. Immun., November 1, 2001; 69(11): 7190 - 7193. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. T. M. Chan, V. Paliwal, J. M. McNiff, S.-H. Park, A. Bendelac, and M. J. Shlomchik Deficiency in {beta}2-Microglobulin, But Not CD1, Accelerates Spontaneous Lupus Skin Disease While Inhibiting Nephritis in MRL-Faslpr Mice: An Example of Disease Regulation at the Organ Level J. Immunol., September 1, 2001; 167(5): 2985 - 2990. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Bergmann-Leitner and S. I. Abrams Differential Role of Fas/Fas Ligand Interactions in Cytolysis of Primary and Metastatic Colon Carcinoma Cell Lines by Human Antigen-Specific CD8+ CTL J. Immunol., May 1, 2000; 164(9): 4941 - 4954. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |